Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Cancer Pain Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Opioids
  • 1.3.3 Non-Steroidal Anti-Inflammatory Drugs
  • 1.3.4 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Cancer Pain Market Share by Application (2019-2025)
  • 1.4.2 Paracetamol Treatment-Related Immunotherapy
  • 1.4.3 Radiotherapy
  • 1.4.4 Chemotherapy
  • 1.4.5 Hormone Therapy
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Cancer Pain Market Size
  • 2.1.1 Global Cancer Pain Revenue 2014-2025
  • 2.1.2 Global Cancer Pain Sales 2014-2025
• 2.2 Cancer Pain Growth Rate by Regions
  • 2.2.1 Global Cancer Pain Sales by Regions 2014-2019
  • 2.2.2 Global Cancer Pain Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Cancer Pain Sales by Manufacturers
  • 3.1.1 Cancer Pain Sales by Manufacturers 2014-2019
  • 3.1.2 Cancer Pain Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Cancer Pain Revenue by Manufacturers (2014-2019)
  • 3.2.2 Cancer Pain Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Cancer Pain Market Concentration Ratio (CR5 and HHI)
• 3.3 Cancer Pain Price by Manufacturers
• 3.4 Key Manufacturers Cancer Pain Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Cancer Pain Market
• 3.6 Key Manufacturers Cancer Pain Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Opioids Sales and Revenue (2014-2019)
  • 4.1.2 Non-Steroidal Anti-Inflammatory Drugs Sales and Revenue (2014-2019)
  • 4.1.3 Others Sales and Revenue (2014-2019)
• 4.2 Global Cancer Pain Sales Market Share by Type
• 4.3 Global Cancer Pain Revenue Market Share by Type
• 4.4 Cancer Pain Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Cancer Pain Sales by Application

6 United States

• 6.1 United States Cancer Pain Breakdown Data by Company
• 6.2 United States Cancer Pain Breakdown Data by Type
• 6.3 United States Cancer Pain Breakdown Data by Application

7 European Union

• 7.1 European Union Cancer Pain Breakdown Data by Company
• 7.2 European Union Cancer Pain Breakdown Data by Type
• 7.3 European Union Cancer Pain Breakdown Data by Application

8 China

• 8.1 China Cancer Pain Breakdown Data by Company
• 8.2 China Cancer Pain Breakdown Data by Type
• 8.3 China Cancer Pain Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Cancer Pain Breakdown Data by Company
• 9.2 Rest of World Cancer Pain Breakdown Data by Type
• 9.3 Rest of World Cancer Pain Breakdown Data by Application
• 9.4 Rest of World Cancer Pain Breakdown Data by Countries
  • 9.4.1 Rest of World Cancer Pain Sales by Countries
  • 9.4.2 Rest of World Cancer Pain Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 BioDelivery Science
  • 10.1.1 BioDelivery Science Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.1.4 Cancer Pain Product Introduction
  • 10.1.5 BioDelivery Science Recent Development
• 10.2 ProStrakan Group
  • 10.2.1 ProStrakan Group Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.2.4 Cancer Pain Product Introduction
  • 10.2.5 ProStrakan Group Recent Development
• 10.3 Teva pharmaceuticals
  • 10.3.1 Teva pharmaceuticals Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.3.4 Cancer Pain Product Introduction
  • 10.3.5 Teva pharmaceuticals Recent Development
• 10.4 Eli-Lilly
  • 10.4.1 Eli-Lilly Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.4.4 Cancer Pain Product Introduction
  • 10.4.5 Eli-Lilly Recent Development
• 10.5 Grunenthal Group
  • 10.5.1 Grunenthal Group Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.5.4 Cancer Pain Product Introduction
  • 10.5.5 Grunenthal Group Recent Development
• 10.6 GW Pharmaceuticals
  • 10.6.1 GW Pharmaceuticals Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.6.4 Cancer Pain Product Introduction
  • 10.6.5 GW Pharmaceuticals Recent Development
• 10.7 Johnson＆Johnson
  • 10.7.1 Johnson＆Johnson Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.7.4 Cancer Pain Product Introduction
  • 10.7.5 Johnson＆Johnson Recent Development
• 10.8 Meda Pharmaceuticals
  • 10.8.1 Meda Pharmaceuticals Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.8.4 Cancer Pain Product Introduction
  • 10.8.5 Meda Pharmaceuticals Recent Development
• 10.9 Orexo
  • 10.9.1 Orexo Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.9.4 Cancer Pain Product Introduction
  • 10.9.5 Orexo Recent Development
• 10.10 Sanofi
  • 10.10.1 Sanofi Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Cancer Pain
  • 10.10.4 Cancer Pain Product Introduction
  • 10.10.5 Sanofi Recent Development
• 10.11 WEX Pharmaceuticals

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Cancer Pain Sales Channels
  • 11.2.2 Cancer Pain Distributors
• 11.3 Cancer Pain Customers

12 Market Forecast

• 12.1 Global Cancer Pain Sales and Revenue Forecast 2019-2025
• 12.2 Global Cancer Pain Sales Forecast by Type
• 12.3 Global Cancer Pain Sales Forecast by Application
• 12.4 Cancer Pain Forecast by Regions
  • 12.4.1 Global Cancer Pain Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Cancer Pain Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response.
The report, states that opioids will continue to dominate as a breakthrough cancer pain treatment, mostly due to available generics and physician familiarity.
In 2019, the market size of Cancer Pain is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Cancer Pain.

This report studies the global market size of Cancer Pain, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Cancer Pain sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Eli-Lilly
Grunenthal Group
GW Pharmaceuticals
Johnson＆Johnson
Meda Pharmaceuticals
Orexo
Sanofi
WEX Pharmaceuticals

Market Segment by Product Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others

Market Segment by Application
Paracetamol Treatment-Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Cancer Pain status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Cancer Pain manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Cancer Pain are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025